Search

Your search keyword '"Masashi, Ogasawara"' showing total 2 results
Start Over Author "Masashi, Ogasawara" Journal bmc ophthalmology
2 results on '"Masashi, Ogasawara"'

1. Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration

Author

Kanako Itagaki, Tetsuju Sekiryu, Akihito Kasai, Yukinori Sugano, Masashi Ogasawara, and Masaaki Saito

Subjects
Aflibercept, Age-related macular degeneration, Polypoidal choroidal vasculopathy, Treat-and-extend, Ophthalmology, RE1-994
Abstract

Abstract Background To evaluate the three-year outcome after intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD). Methods Forty-nine treatment-naïve nAMD patients (50 eyes) were enrolled in this prospective study. The eyes received IAI at two-month intervals in the first year. The treatment regimen was changed to IAI based on a treat-and-extend approach in the second and third years. Results Twenty-nine eyes of 28 patients were successfully followed up over 36 months. The nAMD subtypes included 15 eyes with typical AMD and 14 eyes with polypoidal choroidal vasculopathy. The number of IAIs performed over the 3 years was 17.2 ± 3.1 (mean ± standard deviation). The mean logMAR, which was 0.42 at baseline, improved to 0.19 (P = 0.001) at 12 months, and 0.26 (P = 0.049) at 36 months. The central retinal thickness (CRT) was 329 ± 120 μm at baseline, 151 ± 38 μm (P

Published
2020
Full Text
View/download PDF

2. Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration

Author

Masaaki Saito, Kanako Itagaki, Akihito Kasai, Masashi Ogasawara, Yukinori Sugano, and Tetsuju Sekiryu

Subjects
030213 general clinical medicine, medicine.medical_specialty, genetic structures, Recombinant Fusion Proteins, Visual Acuity, Angiogenesis Inhibitors, 03 medical and health sciences, chemistry.chemical_compound, Macular Degeneration, 0302 clinical medicine, lcsh:Ophthalmology, Japan, Ophthalmology, Age related, Polypoidal choroidal vasculopathy, medicine, Humans, Treat-and-extend, Prospective Studies, Fluorescein Angiography, Prospective cohort study, Aflibercept, Treatment regimen, business.industry, Aflibercept Injection, Age-related macular degeneration, Retinal, General Medicine, Macular degeneration, medicine.disease, eye diseases, medicine.anatomical_structure, Receptors, Vascular Endothelial Growth Factor, Treatment Outcome, chemistry, lcsh:RE1-994, Intravitreal Injections, 030221 ophthalmology & optometry, Choroid, sense organs, business, Tomography, Optical Coherence, medicine.drug, Follow-Up Studies, Research Article
Abstract

Background To evaluate the three-year outcome after intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD). Methods Forty-nine treatment-naïve nAMD patients (50 eyes) were enrolled in this prospective study. The eyes received IAI at two-month intervals in the first year. The treatment regimen was changed to IAI based on a treat-and-extend approach in the second and third years. Results Twenty-nine eyes of 28 patients were successfully followed up over 36 months. The nAMD subtypes included 15 eyes with typical AMD and 14 eyes with polypoidal choroidal vasculopathy. The number of IAIs performed over the 3 years was 17.2 ± 3.1 (mean ± standard deviation). The mean logMAR, which was 0.42 at baseline, improved to 0.19 (P = 0.001) at 12 months, and 0.26 (P = 0.049) at 36 months. The central retinal thickness (CRT) was 329 ± 120 μm at baseline, 151 ± 38 μm (P P P P Conclusion Long-term aflibercept injection can achieve visual improvement and reduce the thickness of the retina and choroid in nAMD. Morphological improvement of these tissues may not be sufficient to sustain earlier visual improvement over the long-term.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results